Biotechnology Company Successfully Completes Pre-IND Meeting With FDA For OUD

For Incannex, this teleconference was a platform to engage with various divisions of the FDA.

May 07, 2024

∙ Paid

Incannex Healthcare Inc. (Nasdaq: IXHL), biotechnology company, specializing in cannabinoid and psychedelic medicine, marked a significant milestone on May 7, 2024, with the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA). This crucial step forward pertains to the development of …

Stock Region Research

Biotechnology Company Successfully Completes Pre-IND Meeting With FDA For OUD

For Incannex, this teleconference was a platform to engage with various divisions of the FDA.

This post is for paid subscribers